Healthcare Industry News:  intended use 

Devices Neurology

 News Release - April 1, 2009

NIMS Exer-Rest(R) Technology Linked to Reduced Brain Damage in Strokes

MIAMI--(HSMN NewsFeed)--Non-Invasive Monitoring Systems, Inc. [NIMS] (OTCBB:NIMU ) announced today that the results of a laboratory investigation published in the April issue of the journal Neuroscience links the technology behind NIMS’ patented Exer-Rest(R) acceleration therapeutic platform to a reduction in brain damage for the major cause of stroke. In their report, “Whole-body periodic acceleration (pGz) reduces brain damage in a focal ischemia model,” Drs. Martinez-Murillo, Serrano, Fernandez and Martinez of CSIC and CIBIR, Madrid & Logroño, Spain concluded that whole body periodic acceleration (WBPA, pGz), the technology behind the Exer-Rest(R), has potential to positively impact on the management of stroke, the third leading cause of death and the major cause of significant disability in adults living in the USA and Europe. They selected this treatment because it increases release of beneficial substances, such as nitric oxide, prostacyclin, prostaglandin E2, and adrenomedullin, from the inner lining of blood vessels into the circulation. These substances protect the brain from damage due to ischemia, i.e., cessation of blood flow to tissue. In their study, the investigators simulated occlusion of a brain blood vessel with clot, the cause of 85% of human strokes. In one group of rats, WBPA was administered for three hours immediately following the simulated stroke, while no treatment was provided to a control group. Magnetic resonance imaging (MRI) conducted 7 days after the simulated stroke revealed 82% less dead brain tissue in the WBPA-treated rats than in the untreated control group. In addition, biochemical markers of brain damage were significantly lower in the WBPA-treated animals.

Marvin A Sackner, M.D., NIMS’ Chief Executive Officer, noted that, “treatment of stroke is yet another potential application of WBPA and the Exer-Rest(R). From our laboratory and clinical studies, we have found that WBPA increases release of clinically meaningful amounts of beneficial substances throughout the body, so that the Martinez-Murillo study’s results are consistent with our expectations.” Drs. Martinez-Murillo and associates commented that world-wide, stroke accounts for 2-4% of total health care costs and more than 4% of direct health care costs in industrialized countries. They concluded that WBPA, “may represent an efficient and affordable method for the treatment of stroke either by itself or in combination with current interventions. Affordability is a big issue if we take into consideration that developing countries account for about two-thirds of nearly 5 million stroke deaths per year.“ They added, “taken together, our results suggest that periodic acceleration may constitute a new non-invasive therapeutic option for the treatment of stroke.”

Steven Mrha, Chief Operating Officer of NIMS stated that WBPA is achieved in humans with the Exer-Rest(R) acceleration therapeutic platform. The Exer-Rest(R) in an FDA approved Class I (exempt) medical device with the following intended uses: “as an aid to temporarily increase local circulation, to provide temporary relief of minor aches and pains, and local muscle relaxation.” The Exer-Rest(R) is a motorized platform that has the appearance of a single or twin bed with a memory foam mattress. A person lying on the mattress is moved repetitively head to foot approximately 140 times per minute during a 30 to 45 minute session. These treatments are usually administered daily five to seven days a week for symptomatic relief. The Exer-Rest(R) WBPA technology is covered by five US patents.

NIMS, an ISO 13485 certified company, is also licensed to sell Exer-Rest(R) in Canada, United Kingdom, the European Common Market and other major world markets. Exer-Rest(R) is regulated outside of the United States as a Class IIa medical device with CE certification.

This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), which statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," and other words of similar meaning. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.


Source: Non-Invasive Monitoring Systems

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



RepFinder 2 - Find Great Medical Independent Sales Reps without recruiter fees.
RepFinder 2 - available on the Apple App Store for iPhone and iPad.